Posted by Michael Wonder on 11 Mar 2023
Maxigesic Rapid tablets gain US FDA approval
10 March 2023 - AFT Pharmaceuticals today announces the US FDA has approved a rapid release tablet form of Maxigesic for the management of mild to moderate acute pain in the US.
The approval for Maxigesic Rapid - a unique, patented combination of 325 mg of paracetamol and 97.5 mg of ibuprofen that deploys a patented rapid release technology – opens an analgesic market to AFT in the US that is worth around US$7.16 billion and is expected to grow by 5.8% a year between now and 2027.
